Cutaneous Leishmaniasis (CL) is one of the world's neglected diseases which is caused by Leishmania spp. The aim of this study was to assess molecular profile and antimony resistance of Leishmania isolated from human and rodent hosts. Samples were collected from suspected CL patients referred to health centres and wild rodent's traps in Gonbad-e-Qabus region, north-eastern Iran. Smears were subjected to PCR-RFLP to identify Leishmania species. In addition, ITS1-PCR products were sequenced for phylogenetic analysis. Clinical isolates and rodent samples were subjected to MTT assay to determine IC50 values and in vitro susceptibilities. Expression levels of antimony resistance-related genes were determined in CL isolates. Out of 1,949 suspected patients with CL and 148 rodents, 1,704 (87.4%) and 6 (4.05%) were positive with direct smear, respectively. Digestion patterns of BusRI (HaeIII) endonuclease enzyme were similar to what expected for Leishmania major. Phylogenetic analysis revealed that the highest interspecies similarity was found between current L. major sequences with L. major obtained from Russia and Uzbekistan. Out of 20 L. major samples tested, 13 (65%) were resistant to meglumine antimoniate (MA) treatment, with an activity index (AI) exceeding 4. The remaining 7 samples (35%) responded to MA treatment and were classified as sensitive isolates, with a confirmed sensitive phenotype based on their AI values. The comparison expression analysis of three major antimony resistance-associated genes in unresponsive clinical isolates demonstrated significant fold changes for TDR1 (4.78-fold), AQP1 (1.3-fold), and γ-GCS (1.17-fold) genes (P < 0.05). Herein, we demonstrate genetic diversity and antimony resistance of L. major isolated from human and reservoir hosts in north-eastern Iran, which could be the basis for planning future control strategies.
Tamiru HF, Mashalla YJ, Mohammed R, Tshweneagae GT. Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area, Northwest Ethiopia. BMC Infect Dis 2019; 19(1): 855. https://doi.org/10.1186/s12879-019-4506-1.
Ziaei Hezarjaribi H, Karamian M, Geran Orimi T, Pagheh AS, Emadi SN, Fakhar M, et al. Phylogenetic position of Leishmania tropica isolates from an old endemic focus in south‐eastern Iran; relying on atypical cutaneous leishmaniasis. Transbound Emerg Dis 2021; 68(3): 1493–503. https://doi.org/10.1111/tbed.13818.
Akhoundi M, Hajjaran H, Baghaei A, Moheb. M. Geographical distribution of Leishmania species of human cutaneous leishmaniasis in Fars Province, Southern Iran. Iranian J Parasitol 2013; 8(1): 85–91.
Mohebali M, Javadian E, Yaghoobi Ershadi M, Akhavan A, Hajjaran H, Abaei M. Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. East Med Health J 2004; 10 (4–5): 591–599.
Kaufer A, Stark D, Ellis J. A review of the systematics, species identification and diagnostics of the Trypanosomatidae using the maxicircle kinetoplast DNA: from past to present. Int J Parasitol 2020; 50(6–7): 449–60. https://doi.org/10.1016/j.ijpara.2020.03.003.
Fouts DL, Manning JE, Wolstenholme DR. Physicochemical properties of kinetoplast DNA from Crithidia acanthocephali, Crithidia luciliae and Trypanosoma lewisi. J Cell Biol 1975; 67(2): 378–399. https://doi.org/10.1083/jcb.67.2.378.
Ghatee MA, Taylor WR, Karamian M. The geographical distribution of cutaneous leishmaniasis causative agents in Iran and its neighboring countries, a review. Front Public Health 2020; 8: 11. https://doi.org/10.3389/fpubh.2020.00011.
Pagheh A, Fakhar M, Mesgarian F, Gholami S, Ahmadpour E. An improved microculture method for diagnosis of cutaneous leishmaniasis. J Parasit Dis 2014; 38(4): 347–51. https://doi.org/10.1007/s12639-013-0316-3.
Pagheh AS, Fakhar M, Mesgarian F, Rahimi-Esboei B, Badiee F. Incidence trend of rural cutaneous leishmaniasis in Gonbad-e-Qabus city, (Golestan, Iran) during 2009–2012. J Maz Univ Med Sci 2013; 23(104): 27–33.
Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. Plos Med 2006; 3(5): e162. https://doi.org/10.1371/journal.pmed.0030162.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19(1): 111–26. https://doi.org/10.1128/CMR.19.1.111-126.2006.
Ghobakhloo N, Motazedian MH, Fardaei M. Expression analysis of multiple genes may involve in antimony resistance among leishmania major clinical isolates from Fars Province, Central Iran. Iran J Parasitol 2016; 11(2): 168.
Oliaee RT, Sharifi I, Afgar A, Kareshk AT, Asadi A, Heshmatkhah A, et al. Unresponsiveness to meglumine antimoniate in anthroponotic cutaneous leishmaniasis field isolates: analysis of resistance biomarkers by gene expression profiling. Trop Med Int Health 2018; 23(6): 622–33. https://doi.org/10.1111/tmi.13062.
Ponte-Sucre A, Gamarro F, Dujardin J-C, Barrett MP, López-Vélez R, García-Hernández R, et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. Plos Negl Trop Dis 2017; 11(12): e0006052. https://doi.org/10.1371/journal.pntd.0006052.
Alizadeh R, Hooshyar H, Bandehpor M, Arbabi M, Kazemi F, Talari A, et al. Detection of drug resistance gene in cutaneous leishmaniasis by PCR in some endemic areas of Iran. Iran Red Crescent Med J 2011; 13(12): 863–7.
Saberi R, Moin-Vaziri V, Hajjaran H, Niyyati M, Taghipour N, Kheirandish F, et al. Identification of Leishmania species using N-acetylglucosamine-1-phosphate transferase gene in a zoonotic cutaneous leishmaniasis focus of Iran. J Vector Borne Dis. 2018 Jan-Mar; 55(1): 14–19. https://doi.org/10.4103/0972-9062.234621.
Darvish J, Siah SR, Mirshamsi KO, Keyvan FN, Hashemi N, Sadeghi SF. Diversity of the rodents of northeastern Iran. Iran J Anim Biosyst 2006; 2(1): 57–76.
de Almeida Ferreira S, Ituassu LT, de Melo MN, de Andrade ASR. Evaluation of the conjunctival swab for canine visceral leishmaniasis diagnosis by PCR–hybridization in Minas Gerais State, Brazil. Vet Parasitol 2008; 152(3–4): 257–63. https://doi.org/10.1016/j.vetpar.2007.12.022.
Schönian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, et al. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis 2003; 47(1): 349–58. https://doi.org/10.1016/s0732-8893(03)00093-2.
Teimouri A, Mohebali M, Kazemirad E, Hajjaran H. Molecular identification of agents of human cutaneous leishmaniasis and canine visceral leishmaniasis in different areas of Iran using internal transcribed spacer 1 PCR-RFLP. J Arthropod Borne Dis 2018; 12(2): 162–171.
Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, et al. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 2004; 279(30): 31010–7. https://doi.org/10.1074/jbc.M403959200.
Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16(2): 111–20. https://doi.org/10.1007/BF01731581.
Saberi R, Fakhar M, Hajjaran H, Abbaszadeh Afshar MJ, Mohebali M, Hezarjaribi HZ, et al. Leishmania RNA virus 2 (LRV2) exacerbates dermal lesions caused by Leishmania major and comparatively unresponsive to meglumine antimoniate treatment. Exp Parasitol. 2022 Oct; 241: 108340. https://doi.org/10.1016/j.exppara.2022.108340.
Saberi R, Fakhar M, Hajjaran H, Ataei-Pirkooh A, Mohebali M, Taghipour N, et al. Presence and diversity of Leishmania RNA virus in an old zoonotic cutaneous leishmaniasis focus, northeastern Iran: haplotype and phylogenetic based approach. Int J Infect Dis. 2020 Dec; 101: 6–13. https://doi.org/10.1016/j.ijid.2020.08.033.
Jorjani O, Kamalinia HR, Mehrbakhsh Z, Ziaei-Hezarjaribi H, Pourrostami K, Mansourian M, et al. Pediatric cutaneous leishmaniasis in Golestan province, Iran: a cross-sectional study of 8-years. Int J Pediatr 2019; 7(8): 9831–9.
Karami M, Doudi M, Setorki M. Assessing epidemiology of cutaneous leishmaniasis in Isfahan, Iran. J Vector Borne Dis 2013; 50(1): 30–37.
Daoui O, Bennaid H, Kbaich MA, Mhaidi I, Aderdour N, Rhinane H, et al. Environmental, climatic, and parasite molecular factors impacting the incidence of cutaneous leishmaniasis due to Leishmania tropica in three Moroccan foci. Microorganisms 2022; 10(9): 1712. https://doi.org/10.3390/microorganisms10091712.
Foroutan M, Khademvatan S, Majidiani H, Khalkhali H, Hedayati-Rad F, Khashaveh S, et al. Prevalence of Leishmania species in rodents: a systematic review and meta-analysis in Iran. Acta Trop 2017; 172: 164–172. https://doi.org/10.1016/j.actatropica.2017.04.022.
Mahmoudzadeh‐Niknam H, Ajdary S, Riazi‐Rad F, Mirzadegan E, Rezaeian A, Khaze V, et al. Molecular epidemiology of cutaneous leishmaniasis and heterogeneity of Leishmania major strains in Iran. Trop Med Int Health 2012; 17: 1335–44. https://doi.org/10.1111/j.1365-3156.2012.03078.x.
Mirzapour A, Spotin A, Behniafar H, Azizi H, Maleki B, Shakeraminia H, et al. Intra-species diversity of Leishmania major and L. tropica from clinical isolates of cutaneous leishmaniasis in southwest Iran inferred by ITS1-rDNA. Iran J Public Health 2019; 48(5): 893.
Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int 2011; 2011: 571242. https://doi.org/10.4061/2011/571242.
Denton H, McGregor JC, Coombs GH. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem J 2004; 381(2): 405–12. https://doi.org/10.1042/BJ20040283.
Sundar S, Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 2007; 56(2): 143–53. https://doi.org/10.1099/jmm.0.46841-0.
Jeddi F, Piarroux R, Mary C. Antimony resistance in Leishmania, focusing on experimental research. J Trop Med 2011; 2011. https://doi.org/10.1155/2011/695382.
Rai S, Goel SK, Nath Dwivedi U, Sundar S, Goyal N. Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS One 2013; 8(9): e74862. https://doi.org/10.1371/journal.pone.0074862.
Mandal S, Maharjan M, Singh S, Chatterjee M, Madhubala R. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and-resistant clinical isolates of Leishmania donovani from India. J Antimicrob Chemother 2010; 65(3): 496–507. https://doi.org/10.1093/jac/dkp468.
Vanaerschot M, Dumetz F, Roy S, Ponte-Sucre A, Arevalo J, Dujardin JC. Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? Expert Rev Anti Infect Ther 2014; 12(8): 937–46. https://doi.org/10.1586/14787210.2014.916614.
Doudi M, Karami M, Eslami G, Setorki M. A study of genetic polymorphism of Crithidiain Isfahan, Iran. Zahedan J Res Med Sci 2015; 17(5): 971.
Spotin A, Rouhani S, Parvizi P. The associations of Leishmania major and Leishmania tropica aspects by focusing their morphological and molecular features on clinical appearances in Khuzestan province, Iran. BioMed Res Int 2014; 2014: 913510. https://doi.org/10.1155/2014/913510.
Ghobakhloo N, Motazedian MH, Naderi S, Ebrahimi S. Isolation of Crithidia spp. from lesions of immunocompetent patients with suspected cutaneous leishmaniasis in Iran. Trop Med Int H 2019; 24(1): 116–126. https://doi.org/10.1111/tmi.13042.